Press Releases
-
Nov 12, 2020
- Barclays Gene Editing & Gene Therapy Summit on November 16 at 1:00pm ETBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in three upcoming virtual conferences. An audio webcast of the presentations will be available live....
-
Nov 9, 2020- Enrolls First Child in Phase 2 Study for Children with Achondroplasia at Risk of Life-Threatening Foramen Magnum Compression
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the Company is expanding its clinical program for vosoritide, an investigational analog of C-type Natriuretic Peptide (CNP), with...
-
Nov 5, 2020- Top-line Results from 52-week Phase 3 Study with Valoctocogene Roxaparvovec for Severe Hemophilia A Expected Early 2021
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 % Change 2020 2019 % Change Total...
-
Nov 4, 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, and Brian Mueller, Executive Vice President, Chief Financial Officer,...
-
Nov 2, 2020If approved, 1st Therapy in U.S. for the Treatment of Achondroplasia
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for vosoritide, an investigational, once...